Found: 12
Select item for more details and to access through your institution.
Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4949, doi. 10.3390/cancers13194949
- By:
- Publication type:
- Article
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
25380 Cholecystokinin-B Receptor -Mediates Growth of Hepatocellular Carcinoma.
- Published in:
- 2021
- By:
- Publication type:
- Abstract
4121 The beneficial, anti-fibrotic effects of chemokine receptor 2 and 5 antagonists on fat-exposed mouse primary hepatic stellate cells (pHSCs).
- Published in:
- 2020
- By:
- Publication type:
- Abstract
4119 Cholecystokinin (CCK) Receptor Antagonist Reverses Nonalcoholic Steatohepatitis (NASH) by Reducing Hepatic Macrophages and Inflammatory Cytokines.
- Published in:
- 2020
- By:
- Publication type:
- Abstract
The role of PI 3-kinase p110β in AKT signally, cell survival, and proliferation in human prostate cancer cells.
- Published in:
- Prostate, 2010, v. 70, n. 7, p. 755, doi. 10.1002/pros.21108
- By:
- Publication type:
- Article
Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 112, n. 6, p. 1271, doi. 10.1002/cpt.2745
- By:
- Publication type:
- Article
Sadistic Personality Disorder: A Review of Data and Recommendations for DSM-IV.
- Published in:
- Journal of Personality Disorders, 1991, v. 5, n. 4, p. 376, doi. 10.1521/pedi.1991.5.4.376
- By:
- Publication type:
- Article
The Role of a Cholecystokinin Receptor Antagonist in the Management of Chronic Pancreatitis: A Phase 1 Trial.
- Published in:
- Pharmaceutics, 2024, v. 16, n. 5, p. 611, doi. 10.3390/pharmaceutics16050611
- By:
- Publication type:
- Article
Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 3, p. 627, doi. 10.3390/pharmaceutics14030627
- By:
- Publication type:
- Article
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 4, p. 3625, doi. 10.3390/ijms24043625
- By:
- Publication type:
- Article
Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 3, p. 1899, doi. 10.3390/ijms23031899
- By:
- Publication type:
- Article